<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713372</url>
  </required_header>
  <id_info>
    <org_study_id>SCT200R/MHNSCCII</org_study_id>
    <secondary_id>CTR20181541</secondary_id>
    <nct_id>NCT03713372</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Study of Evaluating Recombinant Human Anti-EGFR Monoclonal Antibody (SCT200) for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma After Failure of Platinum-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
      monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck
      Squamous Cell Carcinoma after failure of platinum-based therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label, single-arm and multicenter phase II study is designed to evaluate Objective
      Response Rate (ORR) of anti-EGFR monoclonal antibody（SCT200）in Recurrent and/or Metastatic
      Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">May 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>The achievement of any stable disease（SD）, partial response (PR) or complete response (CR), according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progresssion free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time from first dose of SCT200 until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year</time_frame>
    <description>OS is defined as time from first dose of SCT200 until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>1 year</time_frame>
    <description>Serum anti-SCT200 antibody levels before and after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>1 year</time_frame>
    <description>Median scores for each item and domain will be reported at each time point. 30 items questionnaire with answers ranging from 1=not at all to 4=very much includes five functional scales (physical, role, emotional, cognitive and social), three symptom scales (fatigue, nausea &amp; vomiting and pain) and a global health status/QOL scale. Furthermore, it contains six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-H&amp;N35</measure>
    <time_frame>1 year</time_frame>
    <description>European organization for research and treatment of cancer quality of life questionnaire head and neck 35(EORTC QLQ-H &amp; N 35) is a specific questionnaire developed by the European Organisation for Research and Treatment of Cancer for head and neck cancer. The module includes 35 questions Assessing symptoms and side effects of treatment, social function and body image/sexuality .This scale includes seven symptoms subscales that measure pain, swallowing, senses problems, speech problems, trouble with social eating, trouble with social Contact, and less sexuality, and also has 11 subscales related with teeth, opening mouth, dry mouth, sticky saliva, coughing, ill feeling, weight loss, weight gain, use of painkillers, nutritional supplements, and feeding tubes. Standardize the original scores, with scores ranging from 0 to 100, with higher scores representing more serious problems.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Anti-EGFR monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-EGFR monoclonal antibody</intervention_name>
    <description>Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.</description>
    <arm_group_label>Anti-EGFR monoclonal antibody</arm_group_label>
    <other_name>SCT200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily participate in this clinical trial and sign an informed consent form;

          -  Male or female, age ≥ 18 and ≤ 75 years old;

          -  The estimated survival period is ≥ 3 months;

          -  ECOG fitness status score 0 to 1;

          -  Recurrent and/or metastatic HNSCC (except nasopharyngeal carcinoma) diagnosed by
             pathology and unable to receive topical treatment (surgery or radiotherapy);

          -  Patients who have been treated with platinum (cisplatin/carboplatin/nidaplatin) and
             have clear disease progression during treatment (at least 2 cycles) or after treatment
             (see RECIST version 1.1) or side effects Intolerance, and the minimum dose of platinum
             drugs must meet:

               -  Minimum dose of cisplatin: ≥60mg/m2 per cycle, or ≥120mg/m2 in 8 weeks;

               -  The minimum dose of carboplatin: AUC ≥ 4 / cycle, or total AUC ≥ 8 within 8
                  weeks.

               -  If cisplatin is converted to platinum, the platinum dosage can be calculated
                  using the following formula: carboplatin 1AUC = cisplatin 15mg/m2;

               -  The minimum dose of nedaplatin: ≥80mg/m2 per cycle, or ≥160mg/m2 in 8 weeks;
                  Note: Platinum drugs can be used as adjuvant therapy for postoperative patients
                  (synchronous radiotherapy), for palliative chemotherapy in patients with advanced
                  stage or in patients with recurrent and/or metastatic disease.

          -  Laboratory inspection:

               -  Blood routine: neutrophils ≥1.5×l09/L, platelets≥75×109/L, hemoglobin≥80g/L;

               -  Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase
                  (AST), ALT and AST ≤ upper limit of normal value × 3 for liver metastasis, ALT
                  and AST ≤ upper limit of normal value for liver metastases × 5; total bilirubin (
                  TBIL) ≤ upper limit of normal value × 1.5;

               -  Renal function: creatinine (Cr) ≤ normal upper limit × 1.5;

               -  Electrolyte: Magnesium ≥ normal lower limit;

          -  According to the RECIST standard version 1.1, there is at least one measurable tumor
             lesion. For lesions that have received previous radiotherapy, the target lesion can
             only be selected if there is a clear disease progression 3 months after the end of
             radiotherapy.

        Exclusion Criteria:

          -  Patients with a history of central nervous system metastasis or a history of central
             nervous system metastasis before screening. For patients with clinically suspected
             central nervous system metastasis, imaging confirmation must be performed within 28
             days prior to enrollment to exclude central nervous system metastasis;

          -  There are other medical history of malignant tumors, except that the malignant lesions
             have been treated with therapeutic measures 5 years or more before enrollment and
             there are no known active lesions. The investigator judges that the risk of recurrence
             is low; Non-melanoma skin cancer, and no evidence of worsening disease; adequately
             treated cervical cancer in situ, and no evidence of worsening disease; prostatic
             intraepithelial neoplasia, no evidence of prostate cancer recurrence;

          -  known to be allergic to antibodies or other components contained in the test drug;

          -  have received EGFR antibodies (such as panitumumab, cetuximab or its analogs), or
             small molecule EGFR inhibitors (such as gefitinib, erlotinib, lapatinib, etc.);

          -  In the 4 weeks or 4 weeks before enrollment, they received anti-tumor drugs (such as
             chemotherapy, hormone therapy, immunotherapy, antibody therapy, radiotherapy, etc.) or
             received research drug treatment and could not be included in the evaluation by the
             investigator. Pain-free palliative radiotherapy for bones;

          -  At the time of enrollment, patients still had ≥2 toxic side effects (except for hair
             loss, hearing loss, tinnitus, dry mouth or platinum-induced grade 2 neurotoxicity)
             caused by previous anti-tumor treatment;

          -  Patients have been enrolled in other study devices or study drug studies at screening
             time, or have been deactivated for less than or equal to 4 weeks from other study
             drugs or study devices;

          -  Conduct or plan major surgery within 4 weeks prior to enrollment;

          -  Received transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor
             (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 2 weeks
             prior to enrollment;

          -  Clinically significant cardiovascular disease (defined as: unstable angina,
             symptomatic congestive heart failure (New York Heart Association [NYHA] ≥ II),
             uncontrollable severe arrhythmia);

          -  Myocardial infarction occurred within 6 months prior to enrollment;

          -  History of interstitial lung disease (ILD), such as interstitial pneumonia, pulmonary
             fibrosis, or evidence of ILD on baseline chest CT or MRI;

          -  have clinical symptoms, require clinical intervention or serous effusion (such as
             pleural effusion and ascites) with a stabilization time of less than 4 weeks;

          -  medical or psychiatric history or laboratory abnormal medical history that may
             interfere with the interpretation of the results;

          -  Patients who are pregnant or breast-feeding, or who plan to be pregnant during the
             treatment period and within 6 months after the end of treatment;

          -  Patients (including male or female patients) who are unwilling to receive effective
             contraception during the treatment period and within 6 months after the end of
             treatment;

          -  HCV antibody positive; or HIV positive; or HBV test results: HBsAg positive and / or
             HBcAb positive and HBV DNA ≥ 104 copy number or ≥ 2000 IU / ml;

          -  Patients have active or uncontrollable infections (except for simple urinary tract
             infections or upper respiratory tract infections) requiring systemic treatment within
             2 weeks or 2 weeks prior to enrollment;

          -  known patients have alcohol or drug addiction;

          -  The investigator believes that patients have other conditions that may affect their
             adherence to protocol adherence and study indicators, and are not suitable for
             patients participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuankai shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer hospital Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Epidermal growth factor receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>SCT200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

